Transasia Bio-Medicals Profile
Key Indicators
- Authorised Capital ₹ 4.40 Cr
- Paid Up Capital ₹ 4.00 Cr
- Company Age 39 Year, 9 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 108.00 Cr
- Satisfied Charges ₹ 999.70 Cr
- Revenue Growth 23.51%
- Profit Growth 362.81%
- Ebitda 41.32%
- Net Worth -9.90%
- Total Assets -6.18%
About Transasia Bio-Medicals
Transasia Bio-Medicals Limited (TBL) is a leading Public Limited Indian Non-Government Company incorporated in India on 10 May 1985 and has a history of 39 years and nine months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 4.40 Cr and a paid-up capital of Rs 4.00 Cr.
The company currently has active open charges totaling ₹108.00 Cr. The company has closed loans amounting to ₹999.70 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Transasia Bio-Medicals Limited India is Ashok Suthar as COMPANY SECRETARY. Vivek Asrani, Suresh Vazirani, Mala Vazirani, and Five other members serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U33110MH1985PLC036198
- Company No.
036198
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
10 May 1985
- Date of AGM
20 Dec 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Transasia Bio-Medicals Limited offer?
Transasia Bio-Medicals Limited offers a wide range of products and services, including Medical Laboratory Instruments, Pathology Lab Equipments, IVDs & Analyzers, Rapid Test Kit, Corona Test Kit, Hematology Analyzers, Immunoassay Analyzer.
Who are the key members and board of directors at Transasia Bio-Medicals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Ashok Suthar | Company Secretary | 25-Jan-2024 | Current |
Board Members (8)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vivek Asrani  | Director | 01-Jan-2015 | Current |
| Suresh Vazirani | Director | 01-Apr-2008 | Current |
| Mala Vazirani | Director | 03-Dec-2010 | Current |
| Shiraz Homi | Additional Director | 21-Oct-2020 | Current |
| Nishant Saxena | Additional Director | 24-Apr-2024 | Current |
| Sunil Vazirani | Whole-Time Director | 01-May-2024 | Current |
Financial Performance of Transasia Bio-Medicals.
Transasia Bio-Medicals Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 23.51% increase. The company also saw a substantial improvement in profitability, with a 362.81% increase in profit. The company's net worth dipped by a decrease of 9.9%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Transasia Bio-Medicals?
In 2022, Transasia Bio-Medicals had a promoter holding of 100.00%. The company had 2 Subsidiaries and 1 Joint Venture. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Om Pharmaceuticals LimitedVivek Asrani is a mutual person
Concord Enviro Systems LimitedShiraz Homi is a mutual person
Grp LimitedVivek Asrani is a mutual person
Transasia Diagnostics Private LimitedSuresh Vazirani, Mala Vazirani and 2 more are mutual person
- Transasia Instruments Limited
Suresh Vazirani and Mala Vazirani are mutual person
- Transasia Diagnostics Solutions Limited
Suresh Vazirani, Mala Vazirani and 2 more are mutual person
Charges (Loans)
₹108.00 Cr
₹999.70 Cr
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 42.00 Cr
- Citi Bank N.A. : 30.00 Cr
- The Hongkong And Shanghai Banking Corporation Limited : 20.00 Cr
- The Royal Bank Of Scotland N V : 16.00 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Jul 2018 | The Hongkong And Shanghai Banking Corporation Limited | ₹20.00 Cr | Open |
| 21 May 2014 | Citi Bank N.A. | ₹30.00 Cr | Open |
| 07 Sep 2007 | Hdfc Bank Limited | ₹42.00 Cr | Open |
| 30 Apr 2007 | The Royal Bank Of Scotland N V | ₹16.00 Cr | Open |
| 12 Jun 2019 | The Hongkong And Shanghai Banking Corporation Limited | ₹109.84 Cr | Satisfied |
How Many Employees Work at Transasia Bio-Medicals?
Transasia Bio-Medicals has a workforce of 1270 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Transasia Bio-Medicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Transasia Bio-Medicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
